Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7876
-0.0074 (-0.93%)
At close: Sep 12, 2025, 4:00 PM EDT
0.7899
+0.0023 (0.29%)
After-hours: Sep 12, 2025, 7:55 PM EDT
Longeveron Employees
Longeveron had 25 employees as of December 31, 2024. The number of employees increased by 1 or 4.17% compared to the previous year.
Employees
25
Change (1Y)
1
Growth (1Y)
4.17%
Revenue / Employee
$82,920
Profits / Employee
-$747,600
Market Cap
16.59M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 25 | 1 | 4.17% |
Dec 31, 2023 | 24 | 3 | 14.29% |
Dec 31, 2022 | 21 | 1 | 5.00% |
Dec 31, 2021 | 20 | 8 | 66.67% |
Dec 31, 2020 | 12 | -4 | -25.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LGVN News
- 11 days ago - Longeveron® Announces Key Leadership Updates - GlobeNewsWire
- 25 days ago - Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Longeveron Announces Closing Of Up To $17.5 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Longeveron Announces Up To $17.5 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - GlobeNewsWire
- 7 weeks ago - Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - GlobeNewsWire